Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Babesia Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : $0.1 million
Deal Type : Funding
ATCC Announces Subaward to Advance Research for Tickborne Diseases and Vaccine Development
Details : The proceeds will be used to advance babesiosis and tickborne disease research by addressing an underappreciated and understudied area of babesia biology and pathogenesis.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 30, 2024
Lead Product(s) : Babesia Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : $0.1 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATCC supports cancer research and drug discovery with thousands of human and animal cancer cell lines for a better understanding of tumor biology, cancer genomics, tumor biomarkers, and advancing novel therapeutics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable